Curated News
By: NewsRamp Editorial Staff
July 18, 2025
Soligenix's HyBryte(TM) Shows Promise in Early-Stage CTCL Treatment
TLDR
- Soligenix's HyBryte(TM) offers a competitive edge in treating early-stage CTCL, presenting a novel option in a market with limited FDA-approved therapies.
- HyBryte(TM) therapy, administered twice weekly for up to 54 weeks, shows promising results in early-stage CTCL treatment, as per interim IIS data.
- HyBryte(TM) by Soligenix improves CTCL patients' lives, offering hope and a safer alternative in a field lacking new treatments for over a decade.
- Discover how Soligenix's HyBryte(TM) is changing CTCL treatment landscapes with its innovative approach and promising early-stage results.
Impact - Why it Matters
This news is significant for patients suffering from early-stage cutaneous T-cell lymphoma (CTCL), a condition with limited treatment options. The promising results from Soligenix's HyBryte(TM) could herald a new era of effective and safer treatments, addressing a critical gap in CTCL care. For investors and the biotech community, this development underscores Soligenix's potential to lead in innovative therapies for rare diseases, marking a noteworthy advancement in medical science and patient care.
Summary
Soligenix (NASDAQ: SNGX) is making headlines with its HyBryte(TM) treatment showing promising results in early-stage cutaneous T-cell lymphoma (CTCL), a breakthrough that could offer new hope for patients with limited treatment options. Led by Ellen Kim, MD, the ongoing investigator-initiated study (IIS) and the confirmatory phase 3 FLASH2 trial are demonstrating significant success, marking a potential turning point in CTCL treatment. With no new FDA-approved, skin-directed therapies introduced in over a decade, HyBryte(TM)'s synthetic hypericin offers a novel approach to managing early-stage mycosis fungoides, a common type of CTCL. Interim results from the IIS, evaluating extended HyBryte(TM) therapy, have shown promising outcomes at the 18-week evaluation point, underscoring the treatment's potential efficacy and safety.
The collaboration between Soligenix and the Cutaneous Lymphoma Foundation highlights the importance of innovative treatments in addressing unmet medical needs. The recent data not only reinforces the potential of HyBryte(TM) but also positions Soligenix as a key player in the biotech sector's fight against rare diseases. For more details on the study and its implications, visit Read More>> and explore the latest updates in Soligenix's newsroom at https://ibn.fm/SNGX.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's HyBryte(TM) Shows Promise in Early-Stage CTCL Treatment
